Key facts
- Brise Pharma’s last known valuation is $50.0M (Oct 2021).
- It has raised $56.9M.
- Notable investors include Qiming Venture Partners, Shun Xi Fund, Proxima Ventures (China), INCE Capital, Guanghua Kaiyuan Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Brise Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Brise Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Brise Pharma
Developer of new biopharmaceutical drugs intended for treating pain. The company focuses on the development of innovative and highly differentiated analgesic treatments for debilitating pain conditions with large unmet needs, placing a particular emphasis on addressing migraine, neuropathic and musculoskeletal pain, enabling doctors to provide safe, effective, and accessible pain relief solutions for the multitude of patients worldwide grappling with poorly managed pain conditions.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Employees
- 50
- Website
- brisepharma.com/
- Ownership
- Privately Held (backing)
Brise Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Brise Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Brise Pharma in its N-PORT filings yet. We sweep new filings monthly.